Overview of X-Linked Recessive Disorders

X-linked recessive disorders are a group of genetic diseases caused by mutations in genes on the X chromosome, mainly affecting males because males have only one X chromosome while females have two X chromosomes and can usually offset the effect of the mutated gene with another normal X chromosome. The inheritance pattern of X-linked recessive disorders is: if the father carries the mutated gene (and has the disease), and the mother is normal, then all their daughters will carry one mutated gene and one normal gene, becoming carriers but not sick; all their sons will inherit the father's Y chromosome and will not carry the mutated gene. If the mother is a carrier and the father is normal, then any son has a 50% chance of inheriting the mutated gene from the mother (and developing the disease), and any daughter has a 50% chance of inheriting one mutated gene and one normal gene (becoming a carrier), or a 50% chance of inheriting two normal genes. The pathogenesis of X-linked recessive disorders is that some genes on the X chromosome encode some important enzymes or proteins, and when these genes mutate, they cause deficiency or dysfunction of the corresponding enzymes or proteins, resulting in various metabolic disorders or tissue damage. Some common or important names of X-linked recessive disorders are red-green color blindness, hemophilia A, hemophilia B, Fabry disease, erythrocyte glucose-6-phosphate dehydrogenase deficiency, muscular dystrophy, Hunter syndrome, and others.

Red-Green Color Blindness

Red-green colorblindness, also known as deuteranopia, is a common genetic disorder that makes it hard to distinguish red and green colors and their shades. It is usually inherited from recessive genes on the X chromosome. It can affect daily life and work, such as reading traffic lights, maps, and clothing. Red-green colorblindness is caused by defects or the absence of cone cells in the retina that detect light wavelengths. Normally, there are three types of cone cells: red, green, and blue. Red-green colorblindness occurs when the green (M) or red (L) cone cells have gene mutations. These genes are on the X chromosome, so men are more likely to have red-green colorblindness than women because men have only one X chromosome while women have two. The symptoms of red-green colorblindness are difficulty seeing red and green colors and their mixtures, such as brown, purple, pink, etc. There are different types and degrees of red-green colorblindness. The most common type is deuteranomaly, which makes green look more like red. The second most common type is protanomaly, which makes red look more like green. The more severe types are deuteranopia and protanopia, which make green and red disappear or turn gray.

The diagnosis of red-green colorblindness is mainly done by some professional tests, such as the Ishihara test, the anomaloscope test, the Farnsworth-Munsell 100 hue test, etc. These tests use different colors or brightnesses of shapes or numbers to check the ability to identify colors. Generally, if the patient cannot see or distinguish the shapes or numbers in the tests, it means they may have red-green colorblindness. There is no cure for red-green colorblindness yet, but there are some aids that can help improve the perception and recognition of colors. One method is to wear specially designed glasses or contact lenses that filter out some specific wavelengths of light to enhance color contrast. These glasses or contact lenses cannot restore normal color vision, but they can help distinguish red and green to some extent. Another method is to use some digital devices or software that can convert colors into other modes, such as symbols, words, sounds, etc. These devices or software can help identify color information in specific situations. Gene therapy is a potential method to cure red-green colorblindness by introducing normal cone cell genes into the retina to repair defective or missing cone cells. There have been some animal experiments that show gene therapy can effectively restore color perception in animals. However, gene therapy has not been tested in humans yet because it still has some safety and ethical issues. For example, gene therapy may cause immune reactions, infections, cancer, etc., and it may change the patient's original identity and social adaptation ability. Therefore, gene therapy needs more scientific evidence and social discussion before it becomes a feasible and acceptable solution.

Hemophilia A

Hemophilia A is a genetic disorder caused by a lack or defect of clotting factor VIII (FVIII), which leads to increased bleeding and usually affects males. In most cases, it is inherited in an X-linked recessive manner, but some cases are due to spontaneous mutations. According to the US Centers for Disease Control and Prevention (CDC), there are 12 cases of hemophilia A per 100,000 males in the US, and about 400 boys are born with hemophilia A each year. More than half of the people diagnosed with hemophilia A have the severe form. Hemophilia A is four times more common than hemophilia B. Hemophilia A affects all races and ethnic groups. The symptoms of hemophilia A include internal or external bleeding episodes. People with severe hemophilia A have more severe and frequent bleeding, while those with mild hemophilia A usually have more minor symptoms, except after surgery or serious trauma. People with moderate hemophilia A have variable symptoms that range between the severe and mild forms. The diagnosis of hemophilia A mainly relies on indicators such as bleeding time, factor VIII level, and family history. The treatment options include infusions of factor VIII products to prevent and control bleeding. In addition, hemostatic drugs, physical hemostasis, joint protection, and other measures can be used as adjuvant treatments.

Gene therapy is a method that aims to correct the genetic defect by introducing a normal FVIII gene into the patient's body, and it is still in the clinical trial stage. The advantage of gene therapy is that it can provide continuous and stable FVIII levels, thereby reducing or eliminating the risk of bleeding and the need for infusion, improving the quality of life and prognosis. The challenges of gene therapy include how to select the appropriate vector, target cell, dose, and route, how to avoid immune reactions and side effects, and how to monitor and evaluate the safety and efficacy. Currently, there are various gene therapy strategies based on different vectors (such as adeno-associated viruses, retroviruses, or naked plasmids) and different target cells (such as hepatocytes, endothelial cells, or hematopoietic stem cells) that have entered the clinical trial stage, some of which have shown good results and tolerability. For example, a phase I/II trial using adeno-associated virus as a vector to transfect the normal FVIII gene into hepatocytes reported that nine patients with severe hemophilia A did not need infusion of FVIII products for an average of 6.2 years after a single gene therapy session, and their FVIII levels increased from 0.9% to 3.8%. Another phase I/II trial using retrovirus as a vector to transfect the normal FVIII gene into autologous hematopoietic stem cells reported that 10 patients with severe hemophilia A did not need infusion of FVIII products for an average of 3.6 years after a single gene therapy session, and their FVIII levels increased from 0.7% to 2.3%.

In summary, hemophilia A is a genetic disorder caused by a lack or defect of FVIII that leads to increased bleeding and can be treated by infusion of FVIII products and other methods. Gene therapy is a new technology that has the potential to cure hemophilia A, but it still needs further improvement and verification of its safety and efficacy.

Hunter Syndrome

Hunter syndrome is a rare genetic disorder that mainly affects males. It is caused by a lack of an enzyme called iduronate-2-sulfatase, which leads to the accumulation of large sugar molecules called glycosaminoglycans (GAGs) in the body, damaging various organs and tissues. The lack of this enzyme is due to a gene mutation on the X chromosome. The symptoms of Hunter syndrome usually appear between the ages of 2 and 4, and there are two types with different severity levels. The symptoms include coarse facial features such as enlarged nostrils, lips, and tongue; delayed or wide-spaced teeth; a large head; a wide chest; a short neck; stiff joints; hearing loss; growth delay; an enlarged spleen and liver; and white growths on the skin. Severe-type patients also have intellectual disability and neurological deterioration.

The diagnostic methods for Hunter syndrome include urine tests, enzyme activity tests, and gene tests. A urine test can check for abnormally high levels of sugar molecules; an enzyme activity test can check for the deficiency of the iduronate-2-sulfatase enzyme; and a gene test can check for a mutation on the X chromosome. These tests can help doctors determine whether the patient has Hunter syndrome and its type and severity. Currently, the main treatment for Hunter syndrome is enzyme replacement therapy, which involves injecting synthetic iduronate-2-sulfatase enzyme into the vein to help break down GAGs and relieve symptoms. This treatment needs to be done regularly and cannot cure the disease. In addition, there is an emerging gene therapy method that involves introducing normal genes into cells to restore enzyme function. This method is still in clinical trials and may provide more effective and lasting improvement for Hunter syndrome and other genetic disorders. Besides these treatments, symptomatic treatments are also needed for different complications, such as medications, surgery, or other supportive therapies.

References

1. Chiu W, et al. An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials. Int J Mol Sci. 2021 Apr 26;22(9):4534.
2. Hassall MM, et al. Gene Therapy for Color Blindness. Yale J Biol Med. 2017 Dec 19;90(4):543-551.
3. Kruse-Jarres R, et al. Acquired hemophilia A: Updated review of evidence and treatment guidance. Am J Hematol. 2017 Jul;92(7):695-705.
4. Hay CRM, et al. Mortality in congenital hemophilia A - a systematic literature review. J Thromb Haemost. 2021 Jan;19 Suppl 1(Suppl 1):6-20.
5. Cho S, et al. Advances in Hemophilia A Management. Adv Pediatr. 2022 Aug;69(1):133-147.
6. Mohamed S, et al. Mucopolysaccharidosis type II (Hunter syndrome): Clinical and biochemical aspects of the disease and approaches to its diagnosis and treatment. Adv Carbohydr Chem Biochem. 2020;77:71-117.
7. Joseph R, et al. Hunter Syndrome: Is It Time to Make It Part of Newborn Screening? Adv Neonatal Care. 2018 Dec;18(6):480-487.